Eli Lilly is just weeks away from launching Mounjaro in the UK, after getting approval from medicines regulator the MHRA for a new formulation of the drug as a treatment for diabetes and obesity.
The agency has approved a four-dose version of the drug, called Mounjaro KwikPen, which provides a month’s course of GLP-1 and GIP agonist tirzepatide. Great Britain will be the first major market to be supplied with the drug in the multi-shot pen injector format.
